Physician profile
Matthew Feldman
NPI 1104056027
$409,927.45
in general payments reported to CMS, 2019-2025
37 companies · $37K in 2025
The $37K reported for 2025 was more than what 95% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $144K · 2020: $56K · 2021: $70K · 2022: $41K · 2023: $23K · 2024: $39K · 2025: $37K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $66K · Consulting Fee: $14K · Food and Beverage: $7,234 · Honoraria: $6,000 · Travel and Lodging: $4,850 · Education: $57.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $66,349.28 |
| Consulting Fee | $13,964.00 |
| Food and Beverage | $7,234.19 |
| Honoraria | $6,000.00 |
| Travel and Lodging | $4,850.03 |
| Education | $57.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $174,135.84 | 2019-2025 | Dupixent |
| Genzyme Corporation | $155,695.54 | 2019-2025 | |
| Glaxosmithkline, LLC. | $31,491.59 | 2019-2025 | Nucala, Trelegy Ellipta |
| Regeneron Pharmaceuticals, INC. | $18,284.59 | 2019-2022 | |
| Dermavant Sciences, INC. | $10,718.06 | 2024 | Tapinarof |
| Organon LLC | $6,205.64 | 2025 | Vtama |
| Genentech USA, INC. | $4,375.77 | 2019-2025 | Xolair |
| Astrazeneca Pharmaceuticals LP | $2,391.68 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Abbvie INC. | $2,085.36 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $497.61 | 2020-2025 | Takhzyro, Cuvitru, Eohilia |
| Grifols USA, LLC | $372.16 | 2019-2025 | Xembify, Gamunex-C |
| Sanofi-Aventis U.S. LLC | $335.10 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $318.94 | 2023-2025 | |
| Csl Behring | $284.72 | 2019-2024 | Hizentra, Privigen |
| Pfizer INC. | $283.66 | 2020-2025 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $240.35 | 2020-2023 | Auvi-Q |
| Pharming Healthcare, INC. | $239.80 | 2019-2025 | Ruconest |
| Teva Pharmaceuticals USA, INC. | $225.34 | 2019-2023 | |
| Optinose US, INC. | $207.92 | 2019-2024 | |
| Amgen INC. | $186.58 | 2021-2025 | Tezspire |
| Ars Pharmaceuticals Operations, INC. | $177.20 | 2025 | Neffy |
| Galderma Laboratories, L.P. | $147.10 | 2025 | Nemluvio |
| Octapharma USA, INC. | $145.85 | 2020-2024 | Cutaquig |
| Lilly USA, LLC | $88.84 | 2024-2025 | Ebglyss, Taltz |
| Leo Pharma INC. | $81.14 | 2024-2025 | Adbry |
| Alk-Abello, INC | $80.02 | 2019-2025 | Standardized Mite D. Farinae, Timothy, Standardized, Histamine Positive |
| Covis Pharma Gmbh | $78.43 | 2021 | |
| Biocryst US Sales Co., LLC | $77.13 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.50 | 2020-2021 | |
| Shire North American Group INC | $68.31 | 2019 | |
| Azurity Pharmaceuticals, INC. | $62.52 | 2025 | Alvesco |
| Hospira, INC. | $57.34 | 2024-2025 | |
| Gc Biopharma USA, INC. | $51.61 | 2025 | Alyglo |
| Hikma Pharmaceuticals USA | $51.58 | 2022-2024 | Ryaltris |
| Blueprint Medicines Corporation | $46.86 | 2023-2024 | Ayvakit |
| Incyte Corporation | $37.39 | 2022-2025 | Opzelura |
| Biocryst Pharmaceuticals, INC. | $24.38 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Feldman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.